NO993275L - Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser - Google Patents
Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelserInfo
- Publication number
- NO993275L NO993275L NO993275A NO993275A NO993275L NO 993275 L NO993275 L NO 993275L NO 993275 A NO993275 A NO 993275A NO 993275 A NO993275 A NO 993275A NO 993275 L NO993275 L NO 993275L
- Authority
- NO
- Norway
- Prior art keywords
- therapeutic administration
- cd40l compounds
- cd40l
- compounds
- administering anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3467297P | 1997-01-10 | 1997-01-10 | |
| US4015497P | 1997-03-07 | 1997-03-07 | |
| PCT/US1998/000573 WO1998030241A1 (en) | 1997-01-10 | 1998-01-09 | Methods of therapeutic administration of anti-cd40l compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO993275D0 NO993275D0 (no) | 1999-07-01 |
| NO993275L true NO993275L (no) | 1999-09-09 |
Family
ID=26711241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO993275A NO993275L (no) | 1997-01-10 | 1999-07-01 | Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20020071840A1 (ru) |
| EP (1) | EP0966302B1 (ru) |
| JP (1) | JP2001508450A (ru) |
| KR (2) | KR100632846B1 (ru) |
| CN (1) | CN1248921A (ru) |
| AT (1) | ATE356634T1 (ru) |
| AU (1) | AU721697B2 (ru) |
| BR (1) | BR9807471A (ru) |
| CA (1) | CA2277223A1 (ru) |
| CZ (1) | CZ244399A3 (ru) |
| DE (1) | DE69837322T2 (ru) |
| EA (1) | EA001426B1 (ru) |
| EE (1) | EE9900275A (ru) |
| HK (1) | HK1024424A1 (ru) |
| IL (1) | IL130785A0 (ru) |
| IS (1) | IS5101A (ru) |
| NO (1) | NO993275L (ru) |
| NZ (1) | NZ337073A (ru) |
| PL (1) | PL193966B1 (ru) |
| TR (1) | TR199902192T2 (ru) |
| WO (1) | WO1998030241A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| EA002549B1 (ru) * | 1997-05-17 | 2002-06-27 | Байоджен, Инк. | Применение блокатора связывания cd40:cd154 для предотвращения противоадаптивных иммунных реакций, в частности отторжения трансплантата |
| EP1034001B1 (en) * | 1997-06-20 | 2004-08-04 | Biogen Idec MA Inc. | Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
| WO2000016801A1 (en) * | 1998-09-21 | 2000-03-30 | Genetics Institute, Inc. | Methods of downmodulating the immune response to therapeutic proteins |
| EP1101495A4 (en) * | 1999-06-01 | 2003-05-07 | Eisai Co Ltd | PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA |
| GB9927757D0 (en) * | 1999-11-25 | 2000-01-26 | Kennedy Rheumatology Inst | Treatment of autoimmune diseases |
| US20030170231A1 (en) * | 2000-03-06 | 2003-09-11 | Toshihiko Yamauchi | Remedies and preventives for antiphospholipid antibody syndrome |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| CA2781858C (en) | 2000-05-12 | 2015-03-31 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
| JP3785508B2 (ja) * | 2002-04-15 | 2006-06-14 | 学校法人慶應義塾 | 遺伝子治療における免疫応答を解析できる実験モデルマウス |
| DK1562571T3 (da) * | 2002-11-21 | 2011-12-05 | Genzyme Corp | Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning |
| EP2367849B1 (en) | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981724A (en) * | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| KR100398819B1 (ko) * | 1993-09-02 | 2004-02-05 | 트러스티스 오브 다트마우스 칼리지 | gp39길항제를포함하는약제조성물 |
| US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
| ATE188487T1 (de) * | 1993-09-02 | 2000-01-15 | Dartmouth College | Anti-gp39 antikoerper und deren verwendungen |
| CN1137726C (zh) * | 1993-09-02 | 2004-02-11 | 达特茅斯学院理事 | 延长体液免疫抑制的方法 |
| ATE267607T1 (de) * | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| IL125928A (en) * | 1996-03-20 | 2002-11-10 | Bristol Myers Squibb Co | The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations |
-
1998
- 1998-01-09 EA EA199900633A patent/EA001426B1/ru not_active IP Right Cessation
- 1998-01-09 KR KR1020057013115A patent/KR100632846B1/ko not_active IP Right Cessation
- 1998-01-09 PL PL98334500A patent/PL193966B1/pl not_active IP Right Cessation
- 1998-01-09 EE EEP199900275A patent/EE9900275A/xx unknown
- 1998-01-09 WO PCT/US1998/000573 patent/WO1998030241A1/en active IP Right Grant
- 1998-01-09 JP JP53122098A patent/JP2001508450A/ja not_active Ceased
- 1998-01-09 AU AU57353/98A patent/AU721697B2/en not_active Ceased
- 1998-01-09 EP EP98901227A patent/EP0966302B1/en not_active Expired - Lifetime
- 1998-01-09 KR KR1019997006254A patent/KR20000070035A/ko not_active Application Discontinuation
- 1998-01-09 IL IL13078598A patent/IL130785A0/xx unknown
- 1998-01-09 DE DE69837322T patent/DE69837322T2/de not_active Expired - Fee Related
- 1998-01-09 AT AT98901227T patent/ATE356634T1/de not_active IP Right Cessation
- 1998-01-09 CN CN98802832A patent/CN1248921A/zh active Pending
- 1998-01-09 TR TR1999/02192T patent/TR199902192T2/xx unknown
- 1998-01-09 CA CA002277223A patent/CA2277223A1/en not_active Abandoned
- 1998-01-09 NZ NZ337073A patent/NZ337073A/xx unknown
- 1998-01-09 BR BR9807471A patent/BR9807471A/pt not_active Application Discontinuation
- 1998-01-09 CZ CZ992443A patent/CZ244399A3/cs unknown
-
1999
- 1999-06-30 IS IS5101A patent/IS5101A/is unknown
- 1999-07-01 NO NO993275A patent/NO993275L/no not_active Application Discontinuation
-
2000
- 2000-06-28 HK HK00103914A patent/HK1024424A1/xx not_active IP Right Cessation
-
2001
- 2001-12-12 US US10/015,832 patent/US20020071840A1/en not_active Abandoned
-
2004
- 2004-12-23 US US11/021,599 patent/US20050158314A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0966302A1 (en) | 1999-12-29 |
| EA001426B1 (ru) | 2001-02-26 |
| HK1024424A1 (en) | 2000-10-13 |
| NZ337073A (en) | 2001-01-26 |
| US20050158314A1 (en) | 2005-07-21 |
| CN1248921A (zh) | 2000-03-29 |
| EE9900275A (et) | 2000-02-15 |
| IS5101A (is) | 1999-06-30 |
| AU5735398A (en) | 1998-08-03 |
| KR100632846B1 (ko) | 2006-10-16 |
| CZ244399A3 (cs) | 1999-10-13 |
| NO993275D0 (no) | 1999-07-01 |
| DE69837322T2 (de) | 2007-11-22 |
| EA199900633A1 (ru) | 2000-02-28 |
| IL130785A0 (en) | 2001-01-28 |
| AU721697B2 (en) | 2000-07-13 |
| US20020071840A1 (en) | 2002-06-13 |
| DE69837322D1 (de) | 2007-04-26 |
| WO1998030241A1 (en) | 1998-07-16 |
| ATE356634T1 (de) | 2007-04-15 |
| PL334500A1 (en) | 2000-02-28 |
| PL193966B1 (pl) | 2007-04-30 |
| BR9807471A (pt) | 2000-03-21 |
| JP2001508450A (ja) | 2001-06-26 |
| EP0966302B1 (en) | 2007-03-14 |
| CA2277223A1 (en) | 1998-07-16 |
| TR199902192T2 (xx) | 1999-12-21 |
| KR20050088494A (ko) | 2005-09-06 |
| KR20000070035A (ko) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO993275D0 (no) | FremgangsmÕte ved terapeutisk administrering av anti-CD40L-forbindelser | |
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| BR9810841A (pt) | Inibidores de metaloprotease alicìclicos | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| ES2191069T3 (es) | Diaril-2-(5h)-furanonas como inhibidores de cox-2. | |
| ATE189218T1 (de) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
| DK0900200T5 (da) | Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| DE69825154D1 (de) | Pyridazinone als inhibitoren von cyclooxygenase-2 | |
| IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
| PT1039900E (pt) | Agentes terapeuticos | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| HK1043315A1 (en) | Triazineone compounds for treating diseases due tosarcosystis, neospora and toxoplasma. | |
| DK1140103T3 (da) | Ponazuril til behandling af neurologiske og abortfremkaldende sygdomme forårsaget af Coccidia | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| DE69829861D1 (de) | 2-aminopyridine als inhibitoren von cyclooxygenase-2 | |
| ATE248607T1 (de) | Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen | |
| EA199800941A1 (ru) | Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона | |
| MX9704887A (es) | Composiciones farmaceuticas para el tratamiento de trastornos depresivos. | |
| EA200200846A1 (ru) | Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором | |
| LV12459A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |